Carnegie Investment Counsel Cuts Stock Position in Zoetis Inc. $ZTS

Carnegie Investment Counsel lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 304,489 shares of the company’s stock after selling 36,043 shares during the quarter. Carnegie Investment Counsel owned about 0.07% of Zoetis worth $38,311,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC raised its stake in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis during the fourth quarter worth approximately $25,000. Lodestone Wealth Management LLC purchased a new position in Zoetis in the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis in the third quarter worth $31,000. Finally, Holos Integrated Wealth LLC purchased a new position in Zoetis in the fourth quarter worth $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.8%

Shares of ZTS stock opened at $117.86 on Friday. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The stock has a market cap of $49.58 billion, a P/E ratio of 19.58, a P/E/G ratio of 1.83 and a beta of 0.98. The business has a fifty day simple moving average of $122.22 and a 200-day simple moving average of $127.26. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the business posted $1.40 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ZTS shares. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Argus Research reiterates a Buy on Zoetis, providing an analyst-backed reason for investors to consider accumulation on weakness. Argus Research Remains a Buy on Zoetis (ZTS)
• Positive Sentiment: Zacks publishes pieces positioning Zoetis as both a strong momentum stock and a top value pick — these narratives can attract style-driven flows (momentum/value investors). Here’s Why Zoetis (ZTS) is a Strong Momentum Stock
• Positive Sentiment: Zoetis’s most recent quarterly report beat EPS and revenue estimates and management set FY26 EPS guidance in the ~7.00 range — a fundamental positive that supports medium-term upside as investors digest growth and margins.
• Neutral Sentiment: Broker consensus remains mixed with a consensus “Hold” rating from some brokerage coverage, which can cap upside until more uniformly constructive revisions arrive. Zoetis Inc. (NYSE:ZTS) Given Consensus Rating of “Hold” by Brokerages
• Neutral Sentiment: Sector/market commentary (including Zacks/Yahoo pieces highlighting screening tools) may influence near-term flows but are not company-specific catalysts. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Negative Sentiment: Market headlines today report Zoetis shares declining, reflecting short-term profit-taking or broader market weakness rather than new negative fundamental news; this selling pressure is the primary driver of today’s weaker price action. Zoetis (ZTS) Declines More Than Market: Some Information for Investors Zoetis (ZTS) Declines More Than Market: Some Information for Investors

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.